— Know what they know.
Not Investment Advice

NARI NASDAQ

Inari Medical, Inc.
1W: +0.1% 1M: +0.5% 3M: +62.4% 1Y: +35.5% 3Y: +5.6%
$79.97
Last traded 2025-02-19 — delisted
NASDAQ · Healthcare · Medical - Devices · $4.7B mcap · 53M float · 4.57% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$4.7B
52W Range36.73-79.99
Volume2,356,692
Avg Volume2,438,930
Beta1.03
Dividend
Analyst Ratings
4 Buy 8 Hold 0 Sell
Consensus Hold
Company Info
CEOKevin Strange
Employees1,300
SectorHealthcare
IndustryMedical - Devices
IPO Date2020-05-22
6001 Oak Canyon
Irvine, CA 92618
US
877 923 4747
About Inari Medical, Inc.

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Warner Robert Keith U-Tender 12,149 2025-02-19
Tu Thomas A-Award 7,406 2025-02-19
Tu Thomas D-Return 16,599 $56.00 2025-02-19
Tu Thomas D-Return 16,231 $58.44 2025-02-19
Tu Thomas U-Tender 478,767 2025-02-19

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms